Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

NCT01215747 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

261

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: KIACTA (eprodisate disodium)
DRUG: Placebo

Sponsor

C.T. Development America, Inc.